Skip to main content
. 2021 Oct 20;12:716224. doi: 10.3389/fphar.2021.716224

TABLE 5.

Base-case results.

C E CER ICER Special
API 5,877.399 0.940 6,252.553 −187017.543 -
RIV 3,072.136 0.955 3,216.897 - dominant
DAB 3,926.160 0.952 4,124.119 −284674.922 -
VKA 4,325.386 0.820 5,274.862 −9,283.339 -

QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; CER, the cost-effectiveness ratio; API, apixaban; RIV, rivaroxaban; DAB, dabigatran; LMWH/VKA, low molecular weight heparin followed by vitamin K antagonist.